Tango Therapeutics (TNGX) Valuation Scrutinized After Strong One Year Return And Elevated Price To Sales Multiple

Simply Wall St.03-24

AdvertisementWhy Tango Therapeutics Is On Investors’ Radar Tango Therapeutics (TNGX) has drawn attention after a very large 1 year total return of 10.16%, alongside sizeable moves over the past month ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621086205?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-24 02:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621086205","market":"nz","top_or_hot":-1,"title":"Tango Therapeutics (TNGX) Valuation Scrutinized After Strong One Year Return And Elevated Price To Sales Multiple","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Tango Therapeutics Is On Investors’ Radar Tango Therapeutics (TNGX) has drawn attention after a very large 1 year total return of 10.16%, alongside sizeable moves over the past month ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-scrutinized-after-strong-o\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tango Therapeutics (TNGX) Valuation Scrutinized After Strong One Year Return And Elevated Price To Sales Multiple</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTango Therapeutics (TNGX) Valuation Scrutinized After Strong One Year Return And Elevated Price To Sales Multiple\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 02:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-scrutinized-after-strong-o><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Tango Therapeutics Is On Investors’ Radar Tango Therapeutics (TNGX) has drawn attention after a very large 1 year total return of 10.16%, alongside sizeable moves over the past month ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-scrutinized-after-strong-o\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNGX","symbol_name":"Tango Therapeutics Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-scrutinized-after-strong-o","article_id":"2621086205","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-scrutinized-after-strong-o","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621086205","pubTimestamp":1774289377,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Tango Therapeutics Is On Investors’ Radar\nTango Therapeutics (TNGX) has drawn attention after a very large 1 year total return of 10.16%, alongside sizeable moves over the past month and past 3 months.\nFor a precision oncology company still reporting a net loss of US$101.594 million on revenue of US$62.384 million, that kind of share price performance naturally raises questions about how investors are weighing its current fundamentals.\nSee our latest analysis for Tango Therapeutics.\nThe...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TNGX":"Tango Therapeutics Inc."},"translate_title":"Tango Therapeutics(TNGX)在一年强劲回报和市销率提高后估值受到审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":1.5},"content_text":"AdvertisementWhy Tango Therapeutics Is On Investors’ Radar Tango Therapeutics (TNGX) has drawn attention after a very large 1 year total return of 10.16%, alongside sizeable moves over the past month and past 3 months. For a precision oncology company still reporting a net loss of US$101.594 million on revenue of US$62.384 million, that kind of share price performance naturally raises questions about how investors are weighing its current fundamentals. See our latest analysis for Tango Therapeutics. The current US$19.42 share price comes after a sharp 59.18% 1 month share price return and a 117.47% year to date share price return. The 1 year total shareholder return is very large, suggesting investors are reassessing Tango Therapeutics’ risk and opportunity profile. If you are looking for other potential ideas in high growth areas of healthcare, this could be a useful moment to scan 36 healthcare AI stocks. With Tango Therapeutics trading at US$19.42, very close to the latest analyst price target of US$19.67, the key question is whether recent gains leave limited upside or if the market is still underestimating its future growth potential. Preferred Price-to-Sales Multiple of 44.4x: Is It Justified? On current numbers, Tango Therapeutics trades on a P/S of 44.4x, which sits well above both the US Biotechs industry average and its closest peers, even after the recent share price surge to $19.42. The P/S multiple compares the company’s market value to its revenue, which can be useful for loss making businesses where earnings are not yet a guide. For Tango Therapeutics, this means investors are paying a high price today for each dollar of the US$62.384 million in revenue that the business currently generates. Relative to the wider US Biotechs group at 10.7x sales, and peer companies at 6.8x sales, Tango’s 44.4x stands out as aggressively higher. Compared with an estimated fair P/S ratio of 2.4x, the current level implies the market is assigning a valuation that is many times above the level the fair ratio model suggests the multiple could move toward if sentiment or assumptions change. Explore the SWS fair ratio for Tango Therapeutics Result: Price-to-Sales ratio of 44.4x (OVERVALUED) However, the high P/S multiple sits alongside a US$101.594 million loss and early stage clinical pipeline, so any trial setbacks or funding pressures could quickly challenge this optimism. Find out about the key risks to this Tango Therapeutics narrative. Next Steps With enthusiasm running high around Tango Therapeutics, this is a good moment to review the numbers yourself and decide how comfortable you are with the balance of risks and rewards. To see that mix set out clearly, take a closer look at the 1 key reward and 4 important warning signs Looking for more investment ideas? If Tango Therapeutics has caught your attention, do not stop there. Use this moment to widen your watchlist and compare it with other focused stock ideas across the market.  Spot potential value opportunities early by scanning 54 high quality undervalued stocks that pair solid business quality with prices that may not fully reflect their fundamentals. Prioritise resilience by checking 72 resilient stocks with low risk scores for companies with lower risk scores that could help balance out more speculative positions. Hunt for underfollowed opportunities through the screener containing 26 high quality undiscovered gems that highlight quality businesses which may not yet be widely discussed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tango Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621086205","isCrawlerRequest":true}